A practical reference on research compound: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-01 and is reviewed periodically as new material appears.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
== Mechanism of action == P11-4 is an α-peptide that self-assembles into β-sheet amyloids with a hydrogel appearance at low pH. It builds a 3-D bio-matrix with binding sites for calcium ions serving as nucleation point for hydroxyapatite (tooth mineral) formation. The high affinity to tooth mineral is based on matching distances of Ca-ion binding sites on P11-4 and Ca spacing in the crystal lattice of hydroxyapatite. The matrix formation is pH controlled and thus allows control matrix activity and place of formation.
genomic island (GI) A region of a genome that shows evidence of horizontal transfer from another organism. The term is used especially in describing microbial genomes such as those of bacteria, where genomic islands having the same or similar sequences commonly occur in species or strains that are otherwise only distantly related, implying that they were not passed on through vertical descent from a common ancestor but through some form of lateral transfer such as conjugation. These islands often contain functional genes which confer adaptive traits such as antibiotic resistance.
== External links == Amino+Acyl-tRNA+Synthetases at the U.S. National Library of Medicine Medical Subject Headings (MeSH) AARS human gene location in the UCSC Genome Browser. AARS human gene details in the UCSC Genome Browser.
Sources: en.wikipedia.org
==== Acetaminophen ==== One of the main types of drug studies conducted is using astronauts as test subjects and measuring drug dynamics before and after spacecraft flight. A study on acetaminophen pharmacokinetics was performed on ten astronauts, studying its concentration dynamics in saliva two months before spaceflight and during long-term spaceflight. Saliva samples were analyzed at intervals of 0.017, 0.33, 0.5, 0.75, 1, 2, 4, and 6 hours after acetaminophen intake by HPLC with UV spectrophotometric detection at 254 nm. The absorption of acetaminophen during spaceflight was delayed after tablet administration and the bioavailability of the encapsulated drug was found to be moderately decreased. Additionally, the half-life of encapsulated acetaminophen was prolonged during spaceflight.
== Scientific contributions == Du Vigneaud's career was characterized by an interest in sulfur-containing peptides, proteins, and especially peptide hormones. Even before his Nobel-Prize-winning work on elucidating and synthesizing oxytocin and vasopressin via manipulating the AVP gene, he had established a reputation from his research on insulin, biotin, transmethylation, and penicillin. He also carried out a series of structure-activity relationships for oxytocin and vasopressin, perhaps the first of their type for peptides. That work culminated in the publication of a book entitled A Trail of Research in Sulphur Chemistry and Metabolism and Related Fields.
Racemic menthol can also be formed by hydrogenation of thymol, menthone, or pulegone. In both cases with further processing (crystallizative entrainment resolution of the menthyl benzoate conglomerate) it is possible to concentrate the L-enantiomer, however this tends to be less efficient, although the higher processing costs may be offset by lower raw material costs. A further advantage of this process is that D-menthol becomes inexpensively available for use as a chiral auxiliary, along with the more usual L-antipode.
Sources: en.wikipedia.org
=== Plant extracts === Most or all plants produce chemical insecticides to stop insects eating them. Extracts and purified chemicals from thousands of plants have been shown to be insecticidal, however only a few are used in agriculture. In the USA 13 are registered for use, in the EU 6. In Korea, where it is easier to register botanical pesticides, 38 are used. Most used are neem oil, chenopodium, pyrethrins, and azadirachtin. Many botanical insecticides used in past decades (e.g. rotenone, nicotine, ryanodine) have been banned because of their toxicity.
On 21 July 2011, following the exclusion of the original Salernitana club, Salerno mayor Vincenzo De Luca, in compliance with Article 52 of N.O.I.F., assigned the new title to Marco Mezzaroma, brother-in-law of Lazio owner and chairman Claudio Lotito. The new club was admitted to Serie D under the denomination of Salerno Calcio. In the 2011–12 season, Salernitana was immediately promoted to Lega Pro Seconda Divisione after winning Group G of Serie D. On 12 July 2012, the club was renamed US Salernitana 1919. In the 2012–13 Lega Pro Seconda Divisione season, Salernitana finished first in Girone B, and was promoted to Lega Pro Prima Divisione. This was the second consecutive promotion for the team. Finally Salernitana won Group C of Lega Pro and returned Serie B in 2014–15 season. After several seasons at Serie B level, Salernitana won promotion to Serie A at the end of the 2020–21 Serie B season under the tenure of head coach Fabrizio Castori, finishing in 2nd place behind champions Empoli. Promotion was secured with a 3–0 victory over Pescara on the final matchday. Salernitana's return to Serie A however required Lotito and Mezzaroma to sell the club, due to Italian football laws not allowing two clubs from the same owner to play in the same league. On 7 July 2021, the FIGC Federal Council approved the trust of Salernitana to take control of the club, meaning it was officially enrolled in Serie A for the first time in 23 years.
The western regions of Pakistan became a part of the Achaemenid Empire around 517 BCE. In 326 BCE, Alexander the Great conquered the region by defeating various local rulers, most notably, the King Porus, at Jhelum. Among the major powers that ruled the region were the Mauryas (322–185 BCE), during which Ashoka the Great extended the empire. The Indo-Greek Kingdom founded by Demetrius of Bactria (180–165 BCE) included Gandhara and Punjab and reached its greatest extent under Menander (165–150 BCE), allowing the Greco-Buddhist culture in the region to prosper. Taxila had one of the earliest universities and centres of higher education in the world, which was established during the late Vedic period in the 6th century BCE. The ancient university was documented by the invading forces of Alexander the Great and recorded by Chinese pilgrims in the 4th or 5th century CE. At its zenith, the Rai dynasty (489–632 CE) ruled Sindh and the surrounding territories.
In Iceland, flunitrazepam is a controlled substance available from Mylan. It is prescribed for severe insomnia and is sometimes used before surgery to induce a calm, relaxed state of mind for the patient. In Sweden, flunitrazepam is a List II drug (substances with medicinal uses) under the Narcotics Control Act (1968). It was previously available from Mylan, but has been removed from the market in January 2020. In the United Kingdom, flunitrazepam is not licensed for medical use and is a controlled drug under Schedule 3 and Class C. In the United States, the drug has not been approved by the Food and Drug Administration and is considered to be an illegal drug; as of 2016 it is Schedule IV. 21 U.S.C. § 841 and 21 U.S.C. § 952 provide for punishment for the importation and distribution of up to 20 years in prison and a fine; possession is punishable by three years and a fine. Travelers travelling into the United States are limited to a 30-day supply. The drug must be declared to US Customs upon arrival. If a valid prescription cannot be produced, the drug may be subject to Customs search and seizure, and the traveler may face criminal charges or deportation.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.